A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

NCT05074472 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Pancreatic Ductal; Adenocarcinoma
Ovarian Serous Adenocarcinoma
Biliary Cancer Metastatic
Ovarian Serous Cystadenocarcinoma

Interventions

DRUG: ZB131

Sponsor

ZielBio, Inc.